Inovio Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	26.27	44.27	65.81	14.31	46.33	71.14
Short-Term Investments	11.41	14.24	28.3	130.98	206.67	330.17
Cash & Short-Term Investments	37.68	58.51	94.11	145.29	253	401.31
Cash Growth	-44.88%	-37.83%	-35.23%	-42.57%	-36.96%	-2.51%
Accounts Receivable	-	-	-	2.41	11.74	8.03
Other Current Assets	1.76	2.61	3.72	5.41	50.51	39.1
Total Current Assets	39.44	61.12	97.83	153.11	315.24	448.44
Net Property, Plant & Equipment	8.33	9.07	11.77	14.45	17.96	29.02
Other Intangible Assets	-	-	-	-	2.13	2.63
Goodwill	-	-	-	-	10.51	10.51
Long-Term Investments	-	2.1	1.61	2.78	2.01	3.91
Other Long-Term Assets	2.01	2.01	1.98	0.61	0.68	1.43
Total Assets	49.78	74.31	113.2	170.95	348.53	495.94
Accounts Payable	9.27	11.13	17.55	20.92	80.91	48.19
Accrued Expenses	0.82	0.65	2.02	2.37	10.59	10.33
Current Portion of Long-Term Debt	-	-	-	16.77	-	-
Current Portion of Leases	2.91	2.82	2.5	2.41	2.8	2.6
Unearned Revenue	-	-	-	-	-	0.02
Other Current Liabilities	24.93	29.07	13.26	0.11	2.56	4.6
Total Current Liabilities	37.92	43.67	35.33	42.57	96.87	65.74
Long-Term Debt	-	-	-	-	16.61	14.96
Long-Term Leases	5.79	6.55	9.37	11.03	12.66	15.46
Other Long-Term Liabilities	-	-	-	-	0.03	0.11
Total Long-Term Liabilities	5.79	6.55	9.37	11.03	29.3	30.53
Total Liabilities	43.71	50.21	44.69	53.6	126.17	96.27
Common Stock	0.07	0.07	0.04	0.02	0.02	0.22
Additional Paid-in Capital	1,841	1,840	1,799	1,741	1,711	1,610
Accumulated Other Comprehensive Income	-0.64	-0.64	-0.68	-0.66	-0.7	-0.28
Retained Earnings	-1,835	-1,815	-1,730	-1,623	-1,488	-1,210
Shareholders' Equity	6.07	24.1	68.5	117.35	222.36	399.67
Total Liabilities & Equity	49.78	74.31	113.2	170.95	348.53	495.94
Total Debt	8.7	9.37	11.87	30.21	32.07	33.02
Net Cash (Debt)	28.99	49.14	82.25	115.08	220.92	368.29
Net Cash Growth	-49.23%	-40.25%	-28.53%	-47.91%	-40.01%	-1.16%
Net Cash Per Share	0.52	1.05	3.03	5.19	11.11	21.16
Book Value	6.07	24.1	68.5	117.35	222.36	399.67
Book Value Per Share	0.11	0.51	2.52	5.29	11.18	22.97
Tangible Book Value	6.07	24.1	68.5	117.35	209.72	386.53
Tangible Book Value Per Share	0.11	0.51	2.52	5.29	10.55	22.21

SEC Filings: 10-K · 10-Q